儿童失神癫痫治疗前行为及后续药物影响
该随机双盲试验在382例儿童失神癫痫(CAE)患儿中,于基线、第16-20周和12个月时使用儿童行为量表(CBCL)评估行为问题。结果显示,基线时8%的患儿总问题分升高,而丙戊酸组在16-20周时的总问题、外化问题、注意力问题及多动问题评分显著高于乙琥胺组,12个月时注意力问题仍较高,支持乙琥胺作为CAE首选初始治疗。
要点
- CAE患儿基线时8%存在总问题分升高,提示治疗前已有行为问题。
- 丙戊酸在16-20周时行为评分显著劣于乙琥胺,12个月时注意力问题仍较高。
- 无癫痫发作及16-20周Conner持续操作试验置信指数升高与总问题分较差相关。
核心结论
- CAE患儿在治疗前和治疗过程中均存在行为问题。
- 丙戊酸与比乙琥胺或拉莫三嗪更差的行为结局相关,进一步支持乙琥胺作为CAE的首选初始治疗。
研究设计与样本
- 随机双盲试验,比较乙琥胺、拉莫三嗪和丙戊酸在儿童失神癫痫(CAE)患儿中的疗效。
- 基线时382例、第16-20周时310例、12个月时168例参与者有CBCL数据。
- 主要结局指标为CBCL总问题分。
主要发现
- 基线时8%(95%CI 6%-11%)的CAE患儿总问题分升高,平均52.9±10.91。
- 第16-20周,丙戊酸组总问题分为51.7(98.3%CI 48.6-54.7),乙琥胺组为46.5(98.3%CI 43.4-49.6)。
- 第16-20周,丙戊酸组外化问题分为51.4(98.3%CI 48.5-54.3),乙琥胺组为45.8(98.3%CI 42.9-48.7)。
- 第16-20周,丙戊酸组注意力问题分为57.8(98.3%CI 55.6-60.0),乙琥胺组为54.6(98.3%CI 52.4-56.9)。
- 第16-20周,丙戊酸组多动问题分为55.8(98.3%CI 54.1-57.6),乙琥胺组为53.0(98.3%CI 51.3-54.8)。
临床怎么用
- 对于CAE患儿,初始治疗选择乙琥胺可能比丙戊酸或拉莫三嗪带来更好的行为结局。
- 应关注CAE患儿治疗前及治疗过程中的行为问题,尤其是注意力问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize pretreatment behavioral problems and differential effects of initial therapy in children with childhood absence epilepsy (CAE). METHODS: The Child Behavior Checklist (CBCL) was administered at baseline, week 16-20, and month 12 visits of a randomized double-blind trial of ethosuximide, lamotrigine, and valproate. Total problems score was the primary outcome measure. RESULTS: A total of 382 participants at baseline, 310 participants at the week 16-20 visit, and 168 participants at the month 12 visit had CBCL data. At baseline, 8% (95% confidence interval [CI] 6%-11%) of children with CAE had elevated total problems scores (mean 52.9 ± 10.91). At week 16-20, participants taking valproic acid had significantly higher total problems (51.7 [98.3% CI 48.6-54.7]), externalizing problems (51.4 [98.3% CI 48.5-54.3]), attention problems (57.8 [98.3% CI 55.6-60.0]), and attention-deficit/hyperactivity problems (55.8 [98.3% CI 54.1-57.6]) scores compared to participants taking ethosuximide (46.5 [98.3% CI 43.4-49.6]; 45.8 [98.3% CI 42.9-48.7]; 54.6 [98.3% CI 52.4-56.9]; 53.0 [98.3% CI 51.3-54.8]). Lack of seizure freedom and elevated week 16-20 Conner Continuous Performance Test confidence index were associated with worse total problems scores. At month 12, participants taking valproic acid had significantly higher attention problems scores (57.9 [98.3% CI 55.6-60.3]) compared to participants taking ethosuximide (54.5 [95% CI 52.1-56.9]). CONCLUSIONS: Pretreatment and ongoing behavioral problems exist in CAE. Valproic acid is associated with worse behavioral outcomes than ethosuximide or lamotrigine, further reinforcing ethosuximide as the preferred initial therapy for CAE. CLINICALTRIALSGOV IDENTIFIER: NCT00088452. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for children with CAE, valproic acid is associated with worse behavioral outcomes than ethosuximide or lamotrigine.
引用
- Shinnar RC, Shinnar S, Cnaan A, et al. Pretreatment behavior and subsequent medication effects in childhood absence epilepsy. Neurology. 2017. PMID: 28916534. doi:10.1212/WNL.0000000000004514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。